Despite regulatory hurdles, the CBD industry has continued to grow and gain increasing national attention, fueled largely by stories of the cannabinoid’s potential to treat medical conditions, such as rare forms of epilepsy.
While dietary supplements cannot legally treat a disease, producers and marketers of hemp-derived CBD products have nonetheless sought to capitalize on the burgeoning demand for CBD while toeing the line with federal regulators.
In this Healthy INSIDER Podcast, Josh Long, INSIDER’s legal and regulatory editor, and cannabis attorney Garrett Graff discuss:
· The industry’s rationale for disagreeing with FDA’s position that hemp-derived CBD cannot be sold in dietary supplements;
· Measures taken by responsible companies to ameliorate their risks to enforcement actions; and
· Future developments that could provide more certainty for the industry in protecting companies’ investments.
For related coverage on enforcement action taken by FDA against marketers of CBD, check out this blog.